To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Biognosys is the leading proteomics company offering innovative services and products for highly multiplexed protein quantification. Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transforming the life sciences with superior proteomics solutions. Biognosys believes that the decoding of the proteome will impact the life sciences more than the genome revolution a decade ago. Biognosys’ next generation technology quantifies proteins with unbeatable precision and depth. Our solution relies on mass spectrometry, which allows simultaneous quantification of thousands of proteins in a single experiment. This new generation protein quantification technology is available to researchers worldwide through our contract research services or our portfolio of innovative reagent and software products.
Next generation proteomics technology for reproducible and precise protein quantification
Its cutting-edge technology is used in biomarker research, drug and target discovery, pathway modeling, mechanisms of action studies and many other areas. Biognosys offers two distinctive technological platforms for protein analysis: discovery proteomics and targeted proteomics.
- 1LPT - Laboratory of Pharmacology and Toxicology GmbH & Co. KG
- 2Intas Biopharmaceuticals Ltd.
- 3Ranbaxy Laboratories Ltd.
- 4Scientis Pharma SA
- 5Life Technologies Corporation
- 6MEDICE Arzneimittel Pütter GmbH & Co. KG
- 7Sanofi-Aventis Deutschland GmbH
- 8BIOTON S.A.
- 9TranScrip Partners
- 10Abbott GmbH & Co. KG